Agios Pharmaceuticals to Host Financial Results Webcast
Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), based in Cambridge, Massachusetts, is gearing up for an important event as it prepares to host a conference call and live webcast on a Thursday in May 2025. This event will take place at 8:00 a.m. ET, where the company will report its financial outcomes and significant business highlights for the first quarter of 2025. This is a vital opportunity for investors and stakeholders to gain insight into the latest developments and performance of the company.
Accessing the Live Webcast
The live webcast of this event will be easily accessible on the Investors section of Agios's official website. Attendees can find it under the “Events & Presentations” tab. If you happen to miss the live broadcast, don’t worry! A recording of the webcast will be made available on the website approximately two hours after the conclusion of the event, ensuring that all interested parties can catch up on the presentation and discussions.
About Agios Pharmaceuticals
Agios is a trailblazer in the realm of PK activation, devoted to the development of transformative therapies tailored for patients battling rare diseases. In the United States, the company markets an innovative pyruvate kinase (PK) activator specifically designed for adults suffering from PK deficiency. This treatment represents the first disease-modifying therapy for individuals diagnosed with this rare, life-long, debilitating condition characterized by hemolytic anemia.
Innovative Therapies in the Pipeline
Building upon its extensive scientific expertise in classical hematology and its leadership in cellular metabolism, Agios is actively advancing a strong clinical pipeline. This pipeline includes investigational medications targeting diseases such as alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, and anemia associated with myelodysplastic syndrome (MDS). Furthermore, Agios is also working on a preclinical TMPRSS6 siRNA, aiming to explore its potential as a treatment for polycythemia vera. These efforts reflect the company's commitment to enhancing the lives of patients afflicted by rare hematologic diseases.
Company Contacts for Inquiries
Agios invites any interested investors or media personnel to reach out for additional information. The Investor Relations contact is Chris Taylor, who serves as the VP of Investor Relations and Corporate Communications. Interested parties can reach him via email.
Investor Relations Contact
Chris Taylor, VP, Investor Relations and Corporate Communications - Agios Pharmaceuticals. Email: IR@agios.com
Media Relations Contact
Eamonn Nolan, Senior Director of Corporate Communications - Agios Pharmaceuticals. Email: Media@agios.com
Frequently Asked Questions
1. What is the purpose of the conference call?
The conference call aims to discuss Agios's financial results and business highlights for the first quarter of 2025.
2. How can I access the live webcast?
The live webcast will be available on Agios's official website under the “Events & Presentations” section.
3. Will the conference call be recorded?
Yes, a replay of the conference call will be accessible on Agios’s website approximately two hours after the event concludes.
4. What conditions does Agios focus on?
Agios specializes in therapies for rare diseases, particularly those related to PK deficiency, thalassemias, sickle cell disease, and MDS-associated anemia.
5. Who can I contact for more information?
For more inquiries, you can reach out to Chris Taylor for investor-related questions and Eamonn Nolan for media perspectives via their respective emails.
